Rafferty Asset Management’s Gritstone bio, Inc. Common Stock GRTS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-23,628
Closed -$65.7K 1154
2023
Q1
$65.7K Sell
23,628
-35,153
-60% -$100K ﹤0.01% 1132
2022
Q4
$203K Sell
58,781
-3,056
-5% -$8.72K ﹤0.01% 1083
2022
Q3
$159K Buy
61,837
+12,400
+25% +$39.5K ﹤0.01% 1107
2022
Q2
$120K Sell
49,437
-149,608
-75% -$393K ﹤0.01% 1063
2022
Q1
$820K Sell
199,045
-270,194
-58% -$1.43M ﹤0.01% 822
2021
Q4
$6.03M Buy
+469,239
New +$5.2M 0.03% 302

Other funds holding GRTS

Rafferty Asset Management's GRTS Position: Q2 2023 in Review

Rafferty Asset Management sold out of Gritstone bio, Inc. Common Stock (GRTS) in Q2 2023, closing a stake of 23,628 shares — an estimated $65.7K sold.

Rafferty Asset Management first reported a position in GRTS in Q4 2021 and held it in 6 quarters. The position peaked at $6.03M in Q4 2021. 88 funds tracked by Wall St. Rank hold GRTS as of Q2 2023.

  • Rafferty Asset Management reported no remaining Gritstone bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Rafferty Asset Management sold 23,628 Gritstone bio, Inc. Common Stock shares in Q2 2023, an estimated $65.7K.
  • Rafferty Asset Management first reported a position in Gritstone bio, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Rafferty Asset Management's Gritstone bio, Inc. Common Stock position peaked at $6.03M in Q4 2021.
  • 88 funds tracked by Wall St. Rank held Gritstone bio, Inc. Common Stock as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.